Actelion

This study tested the drug bosentan in 18 adults with systemic sclerosis who had reduced blood flow in their hands and a history of digital ulcers. The goal was to see if bosentan could improve hand blood flow measured by laser imaging and how blood flow relates to ulcer severity…

This Phase 2 trial tested whether adding bosentan, a drug used for blood vessel conditions, to standard chemotherapy (dacarbazine) could slow tumor growth in people with stage IV melanoma. The study enrolled 80 adults with advanced melanoma and compared the combination to chemoth…

This study looked at whether bosentan (Tracleer) can reduce the thickness of lung artery walls in people with a type of high blood pressure in the lungs (pulmonary arterial hypertension, or PAH). Eleven adults with PAH took bosentan for 6 months. Researchers measured artery wall …

This study tested the drug macitentan in 165 children with pulmonary arterial hypertension (PAH), a serious lung condition. The children were randomly assigned to receive macitentan or standard care. The main goal was to see how the drug behaves in the body and whether it is safe…

This study tested whether a single pill containing two drugs (macitentan and tadalafil) works better than taking either drug alone for people with pulmonary arterial hypertension (PAH), a serious lung condition. 187 adults with PAH took either the combination pill or one of the s…

This large Phase 3 study tested whether selexipag, a daily pill, can delay serious complications or death in people with pulmonary arterial hypertension (PAH), a rare condition of high blood pressure in the lungs. Over 1,100 adults with PAH received either selexipag or a placebo.…

This study tested a new drug called ACT-293987 (NS-304) in 43 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the lungs. The trial had two parts: first, a single dose to check how it affects blood flow, then 21 weeks where some peo…

This Phase 2 trial tested whether selexipag, a drug that opens blood vessels, can reduce the number of Raynaud's attacks in adults with systemic sclerosis. 74 participants took either selexipag or a placebo twice daily. The main goal was to see if the drug lowered weekly attack f…